A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
Recruiting
Phase 2
Interventional Study
Moderate to Severe Vernal Keratoconjunctivitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 4 – 17
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Laboratoires Thea · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Main Inclusion Criteria:
* Informed consent signed and dated
* Male or female participant from 4 years to less than 18 years old.
* Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.
Main Exclusion Criteria:
Participants must not have any conditi…
Contacts